MAPT and Alzheimer disease: Various biomarkers associated with later stages of AD have been suggested [5] including cerebrospinal fluid (CSF) and plasma biomarkers indicative of amyloid deposition, neuronal damage and loss, and the formation of NFTs, notably phosphorylated-tau (P-tau), Aβ42, total-tau (T-tau), as well as neurofilament light protein (NFL) [6, 7], while plasma concentrations of Aβ40 and Aβ42 may not be as useful in diagnosing AD [6, 8].